Tesirine| SG3249;SG-3249

Cas No.:	1595275-62-9
Chemical Name:	Tesirine
Synonyms:	Tesirine;MP-PEG8-VA-PABC-PBD Dimer;8DVQ435K46;SG3249;N-[31-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-29-oxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriaconta
SMILES:	O([H])[C@@]1([H])[C@]2([H])C([H])([H])C(C([H])([H])[H])=C([H])N2C(C2=C([H])C(=C(C([H])=C2N1C(=O)OC([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])N([H])C([C@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C(C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])N([H])C(C([H])([H])C([H])([H])N1C(C([H])=C([H])C1=O)=O)=O)=O)=O)=O)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])OC1=C(C([H])=C2C(=C1[H])N=C([H])[C@]1([H])C([H])([H])C(C([H])([H])[H])=C([H])N1C2=O)OC([H])([H])[H])OC([H])([H])[H])=O
Formula:	C₇₅H₁₀₁N₉O₂₃
M.Wt:	1496.6510
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Tesirine ( SG3249) is a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer as antibody-drug conjugate (ADC) payload; Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics; Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in small-cell lung cancer.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC74470	SuO-Val-Cit-PAB-MMAE	A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB..
DC71665	Val-Cit-PAB-MMAF	Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
DC71664	Val-Cit-PAB-MMAF sodium	Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
DC71115	SN38 NHS ester	SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs).
DC48401	TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride	TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugate for ADC with potent antitumor activity by using TLR7/8 agonist 4, linked via the cleavable ADC linker hydroxy-PEG10-acid.
DC40875	MC-DM1	MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC).
DC40590	DBCO-PEG4-MMAF	DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.
DC40468	Mc-VC-PAB-SN38	Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).
DC11013	Tesirine	Tesirine ( SG3249) is a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer as antibody-drug conjugate (ADC) payload.
DC8539	DM1-SMCC	DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate.